Archives for Neuropsychiatry

Carlat Psychiatry Report

Cognitive Deficits in Schizophrenia

Lately, you’ve probably seen a lot of articles in the journals (not to mention in the journal ads) about targeting cognition in schizophrenia. Latuda (lurasidone), the latest FDA approved antipsychotic, is being talked up to have “pro-cognitive” effects—whatever that means. (See accompanying article by...
Continue Reading



Antidepressants

Research Updates in Psychiatry

ATYPICAL ANTIPYSCHOTICS strong>Abilify for Depression and Bipolar Disorder: A Meta-Analysis Abilify (aripiprazole), which has long been FDA-approved for both schizophrenia and manic episodes of bipolar disorder, was recently approved for augmentation of antidepressants in patients with treatment-resistant depression. But there has been controversy about...
Continue Reading



Carlat Psychiatry Report

Vagus Nerve Stimulation: A Brief Update

VNS (vagus nerve stimulation) was initially developed and approved for treatment-refractory epilepsy. Cyberonics conducted one sham-controlled study for treatment-resistant depression, and while this double-blind study showed no statistical benefit over placebo, an open-label extension showed enough benefit to impress someone at the FDA. In...
Continue Reading



12